Date: 2014-11-06
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Amgen (USA - CA)
Product: AMG 224
Action
mechanism: antibody drug conjugate.
Disease: multiple myeloma
Therapeutic area: Cancer - Oncology
Country: Australia, USA
Trial
details: This first in human phase 1 multicenter open label study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 224 in subjects with relapsed or refractory multiple myeloma. (NCT02561962)
Latest
news: * On November 6, 2014, a Phase I trial sponsored by Amgen was published on the NIH website ClinicalTrials.gov for AMG 176 and is currently recruiting participants.
